ArticleFrontiers in cellular and infection microbiology2024
Clinical and genomic characterization of carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- NDM-ProducingJournal of clinical medicine · 2026Article
- Incidence proportion and divergent performance of risk factors for carbapenem-resistant Gram-negative bacteria bloodstream infections across haematological cohorts.JAC-antimicrobial resistance · 2026Article
- A machine learning-driven multitask framework for antibiotic resistance prediction in Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae bloodstream infections among hematological malignancy patients.Antimicrobial resistance and infection control · 2026Article
- Risk factors for antibiotic resistance and 30-day mortality among adult patients with acute leukemia and Escherichia coli bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.Diagnostics (Basel, Switzerland) · 2026Review
- Clinical Outcomes of Bloodstream Infections in Liver Transplant Recipients: A Ten-Year Single-Center Retrospective Analysis, from Türkiye.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Clinical Characteristics and Outcomes of Carbapenem-Resistant Gram-Negative Bacteria Pneumonia in Immunocompromised ICU Patients: A Retrospective Study.Infection and drug resistance · 2026Article
- Intestinal colonization of carbapenem-resistant gram-negative bacteria in pediatric hematology patients: risk factors and molecular characteristics, a multicenter case-control study.BMC microbiology · 2025Article
- The potential of the microbiome as a target for prevention and treatment of carbapenem-resistant Enterobacteriaceae infections.Frontiers in cellular and infection microbiology · 2025Review
- Incidence and risk factors of active carbapenem-resistant enterobacteriaceae surveillance in hematology patients: a propensity score matching study.Frontiers in microbiology · 2025Article
- Genomic characterization ofFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: This retrospective study examined the characteristics and clinical outcomes of patients with Results: A total of 301 patients with Conclusions: CRE BSIs are a frequent complication in patients with hematological malignancies undergoing treatment and are associated with poor survival rates. A comprehensive understanding of risk factors and ongoing surveillance of prevalent strains are essential for the effective management of these infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.